Don’t miss ProBio and GlyTherix Live Webinar on 6th December
Speaker LinkedIn profile link
Brad founded GlyTherix to bring to market an innovative antibody for treatment of solid tumours from cancers. His career in biotechnology began with a PhD in protein chemistry, he has led research groups in government agencies, universities and hospitals and was a key part of the establishment of a national proteomics facility, APAF. He continues to be active in research collaborations and academic supervision and in 2015 was a joint recipient of one of Australia’s most prestigious science awards, a Eureka Prize, for Interdisciplinary Research. He has co-authored 105 peer reviewed papers and book chapters and seven patents.
Radioimmunotherapy (RIT) is an emerging approach for the diagnosis, therapy, and monitoring of solid tumors. Often using paired agents, each targeting the same tumor molecule, but labelled with an imaging or therapeutic isotope, radioimmunotherapy has achieved promising clinical results in relatively radio-resistant solid tumors such as prostate.
The clinical use and optimization of a radioimmunotherapy approach is, in part, influenced by the targeted tumor antigen, several of which have been proposed for different solid tumors.
Glypican-1 (GPC-1) is a heparan sulfate proteoglycan (HSPG) overexpressed in multiple cancers. Multiple studies indicate the prominence of this cancer biomarker with significant diagnostic and therapeutic potential.
Recent advances in monoclonal antibody (mAb)-based biopharmaceuticals targeting GPC-1 show promise toward managing GPC-1-positive solid tumors clinically. However, a key challenge in RIT is the manufacture of the antibody to obtain a high yield stable product that can be distributed to treatment centers. Using the patented anti-GPC-1 Miltuximab® as a case study for new cancer treatment, we have illustrated a pathway:
- to achieve manufacture of the molecules suitable to treat large pools of patients
- for preclinical to clinical translation
Related Service
